PDCD5 inhibits osteosarcoma cell metastasis via targeting TGF-β1/Smad signaling pathway and is associated with good prognosis.
EMT
PDCD5
TGF-β1
invasion
metastasis
osteosarcoma
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2019
2019
Historique:
received:
16
04
2018
accepted:
04
01
2019
entrez:
23
3
2019
pubmed:
23
3
2019
medline:
23
3
2019
Statut:
epublish
Résumé
Whether programmed cell death 5 (PDCD5) is effective for tumor metastasis remains unclear. In this study, the expression of PDCD5 in 63 osteosarcoma (OS) tissues and two OS cell lines was analyzed. Then the relationship between PDCD5 expression and clinicopathological features of OS was studied. In addition, adhesion, wound healing, Transwell and Matrigel tube formation assays were used to explore the role of PDCD5 in OS cell adhesion, migration, invasion and angiogenesis. Western blotting was used to detect the protein expression of TGF-β1/Smad signaling pathway and epithelial-mesenchymal transition (EMT)-related markers. At the same time, key molecules involved in migration, invasion and EMT in tumor specimens were assessed by immunohistochemistry. The data showed that PDCD5 overexpression significantly attenuated OS cell adhesion, migration, invasion and angiogenesis. Furthermore, PDCD5 knockdown caused an opposite effect on these phenotypes
Types de publication
Journal Article
Langues
eng
Pagination
1116-1128Déclaration de conflit d'intérêts
None.
Références
N Engl J Med. 2001 Feb 22;344(8):539-48
pubmed: 11207349
Semin Cancer Biol. 2001 Oct;11(5):327-37
pubmed: 11562175
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15089-94
pubmed: 11752456
Zhonghua Zhong Liu Za Zhi. 2000 Mar;22(2):102-4
pubmed: 11776632
Oncogene. 2003 Sep 29;22(42):6524-36
pubmed: 14528277
Apoptosis. 2006 Jan;11(1):101-11
pubmed: 16374546
Apoptosis. 2006 Jun;11(6):993-1001
pubmed: 16547588
Cell. 2008 Jul 25;134(2):215-30
pubmed: 18662538
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
Oncogene. 2011 Aug 25;30(34):3682-93
pubmed: 21441952
Cancer Res. 2011 Sep 1;71(17):5606-10
pubmed: 21862631
Med Oncol. 2013 Dec;30(4):697
pubmed: 23975634
Int J Oncol. 2014 Jan;44(1):153-60
pubmed: 24173774
PLoS One. 2014 Mar 11;9(3):e91332
pubmed: 24618693
Eur J Cancer. 2014 Sep;50(13):2336-50
pubmed: 25001183
Cancer Lett. 2015 Apr 10;359(2):241-9
pubmed: 25617801
Int J Clin Exp Med. 2014 Dec 15;7(12):5429-36
pubmed: 25664052
Mol Cancer. 2015 Apr 17;14:86
pubmed: 25890345
Oncotarget. 2015 Jun 30;6(18):16517-26
pubmed: 26203049
Curr Opin Pediatr. 2016 Feb;28(1):26-33
pubmed: 26626558
Tumour Biol. 2016 Jun;37(6):7951-7
pubmed: 26700675
Expert Rev Anticancer Ther. 2016 May;16(5):543-56
pubmed: 26999418
Anticancer Drugs. 2016 Aug;27(7):660-8
pubmed: 27243922
IUBMB Life. 2016 Jul;68(7):597-601
pubmed: 27255549
Springerplus. 2016 Jul 07;5(1):988
pubmed: 27398268
Br J Cancer. 2017 Jan 3;116(1):91-99
pubmed: 27898661
Cancer Lett. 2017 Oct 1;405:90-99
pubmed: 28774797
J Exp Clin Cancer Res. 2017 Oct 11;36(1):141
pubmed: 29020987
Biochem Biophys Res Commun. 2018 Jan 1;495(1):27-34
pubmed: 29032182
Expert Rev Anticancer Ther. 2018 Jan;18(1):39-50
pubmed: 29210294
Tohoku J Exp Med. 1998 Feb;184(2):133-42
pubmed: 9605020
Biochem Biophys Res Commun. 1999 Jan 8;254(1):203-10
pubmed: 9920759